Showing 511-520 of 1539 results for "".
Scientifically Speaking: Injecting Fillers in the Lips, Chin, and Jaw
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-injecting-fillers-in-the-lips-chin-and-jaw/20000/How do experts balance patient preference and their own aesthetic when they treat the lower face with aesthetic injectables? Learn about strategies to achieve natural-looking, impressive improvements in the lips, chin, and jawline. Michael Somenek, MD; Kay Durairaj, MD; Shino Bay Aguilera, DO; and COn the Leading Edge, Not the Bleeding Edge: Joe Niamtu, DMD
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/on-the-leading-edge-not-the-bleeding-edge-joe-niamtu-dmd/18606/Innovator, influencer, and podium perennial Joe Niatmu, III, DMD has built a successful surgical aesthetic practice by focusing on the basics, concentrating on his strengths, and avoiding passing fads. How does he stay passionate, spot the best new developments, and build a fulfilling practice? In tHelping Patients Look Like Their Best Personal Self
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/shamban/18973/Has someone come into your office asking to look radically different? That's a big red flag warning for Ava Shamban, MD, owner and director of two dermatological practices in Santa Monica and Beverly Hills, Calif., frequent TV commentator, and author of the book, “Heal Your Skin: The Breakthrough PlThe Importance of Mentorship
https://practicaldermatology.com/youngmd-connect/wrap-ups/the-importance-of-mentorship/26950/The Importance of MentorshipSkin Cancer Prevention Through Photoprotection: What Your Patients Should Know
https://practicaldermatology.com/topics/skin-cancer-photoprotection/skin-cancer-prevention-through-photoprotection-what-your-patients-should-know/26540/Skin Cancer Prevention Through Photoprotection: What Your Patients Should KnowMonoclonal Antibodies for Restoring a Healthy Skin Microbiome in Atopic Dermatitis Patients
https://practicaldermatology.com/topics/research-update/monoclonal-antibodies-restoring-healthy-skin-microbiome-atopic-dermatitis-patients/24566/Monoclonal Antibodies for Restoring a Healthy Skin Microbiome in Atopic Dermatitis PatientsDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PAtopic Dermatitis Journal Club: AD Guidelines May Represent a ‘Paradigm Shift’ in Care
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/atopic-derm-journal-club-ad-guidelines-may-represent-a-paradigm-shift-in-care/24075/In the first video of this series, Derek Chu, MD and Peter Lio, MD talk about new atopic dermatitis (AD) guidelines from the American Academy of Allergy, Asthma and Immunology Joint Task Force. These guidelines potentially represent a reshaping of the approach to AD care and understanding, accordingASLMS New Beginnings Initiative
https://practicaldermatology.com/programs/practical-dermatology/aslms-new-beginnings-initiative/18188/In 2014, the American Society for Laser Medicine and Surgery started its New Beginnings initiative. Initially launched to benefit cancer survivors, ASLMS physicians volunteered to remove radiation tattoos pro bono. Recently, the ASLMS, under the leadership of its president Paul Friedman, MD, expandeThe Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market avail